Ailanthone targets p23 to overcome MDV3100 resistance in castration-resistant prostate cancer
Prostate cancers often become castration resistant due to alternative expression of androgen receptor (AR) splice variants. Here, the authors screened a library of natural compounds and identified Ailanthone as a potent inhibitor of AR through its binding to the co-chaperone protein p23 that, by pre...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2016-12-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/ncomms13122 |
| id |
doaj-397854b72c3a42d8b708521339c3ef2d |
|---|---|
| record_format |
Article |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Yundong He Shihong Peng Jinhua Wang Huang Chen Xiaonan Cong Ang Chen Meichun Hu Min Qin Haigang Wu Shuman Gao Liguo Wang Xin Wang Zhengfang Yi Mingyao Liu |
| spellingShingle |
Yundong He Shihong Peng Jinhua Wang Huang Chen Xiaonan Cong Ang Chen Meichun Hu Min Qin Haigang Wu Shuman Gao Liguo Wang Xin Wang Zhengfang Yi Mingyao Liu Ailanthone targets p23 to overcome MDV3100 resistance in castration-resistant prostate cancer Nature Communications |
| author_facet |
Yundong He Shihong Peng Jinhua Wang Huang Chen Xiaonan Cong Ang Chen Meichun Hu Min Qin Haigang Wu Shuman Gao Liguo Wang Xin Wang Zhengfang Yi Mingyao Liu |
| author_sort |
Yundong He |
| title |
Ailanthone targets p23 to overcome MDV3100 resistance in castration-resistant prostate cancer |
| title_short |
Ailanthone targets p23 to overcome MDV3100 resistance in castration-resistant prostate cancer |
| title_full |
Ailanthone targets p23 to overcome MDV3100 resistance in castration-resistant prostate cancer |
| title_fullStr |
Ailanthone targets p23 to overcome MDV3100 resistance in castration-resistant prostate cancer |
| title_full_unstemmed |
Ailanthone targets p23 to overcome MDV3100 resistance in castration-resistant prostate cancer |
| title_sort |
ailanthone targets p23 to overcome mdv3100 resistance in castration-resistant prostate cancer |
| publisher |
Nature Publishing Group |
| series |
Nature Communications |
| issn |
2041-1723 |
| publishDate |
2016-12-01 |
| description |
Prostate cancers often become castration resistant due to alternative expression of androgen receptor (AR) splice variants. Here, the authors screened a library of natural compounds and identified Ailanthone as a potent inhibitor of AR through its binding to the co-chaperone protein p23 that, by preventing AR interaction with HSP90, results in ubiquitin/proteasome-mediated degradation of the receptor. |
| url |
https://doi.org/10.1038/ncomms13122 |
| work_keys_str_mv |
AT yundonghe ailanthonetargetsp23toovercomemdv3100resistanceincastrationresistantprostatecancer AT shihongpeng ailanthonetargetsp23toovercomemdv3100resistanceincastrationresistantprostatecancer AT jinhuawang ailanthonetargetsp23toovercomemdv3100resistanceincastrationresistantprostatecancer AT huangchen ailanthonetargetsp23toovercomemdv3100resistanceincastrationresistantprostatecancer AT xiaonancong ailanthonetargetsp23toovercomemdv3100resistanceincastrationresistantprostatecancer AT angchen ailanthonetargetsp23toovercomemdv3100resistanceincastrationresistantprostatecancer AT meichunhu ailanthonetargetsp23toovercomemdv3100resistanceincastrationresistantprostatecancer AT minqin ailanthonetargetsp23toovercomemdv3100resistanceincastrationresistantprostatecancer AT haigangwu ailanthonetargetsp23toovercomemdv3100resistanceincastrationresistantprostatecancer AT shumangao ailanthonetargetsp23toovercomemdv3100resistanceincastrationresistantprostatecancer AT liguowang ailanthonetargetsp23toovercomemdv3100resistanceincastrationresistantprostatecancer AT xinwang ailanthonetargetsp23toovercomemdv3100resistanceincastrationresistantprostatecancer AT zhengfangyi ailanthonetargetsp23toovercomemdv3100resistanceincastrationresistantprostatecancer AT mingyaoliu ailanthonetargetsp23toovercomemdv3100resistanceincastrationresistantprostatecancer |
| _version_ |
1721447815964524544 |
| spelling |
doaj-397854b72c3a42d8b708521339c3ef2d2021-05-11T10:36:58ZengNature Publishing GroupNature Communications2041-17232016-12-017111410.1038/ncomms13122Ailanthone targets p23 to overcome MDV3100 resistance in castration-resistant prostate cancerYundong He0Shihong Peng1Jinhua Wang2Huang Chen3Xiaonan Cong4Ang Chen5Meichun Hu6Min Qin7Haigang Wu8Shuman Gao9Liguo Wang10Xin Wang11Zhengfang Yi12Mingyao Liu13East China Normal University and Shanghai Fengxian District Central Hospital Joint Center for Translational Medicine, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal UniversityEast China Normal University and Shanghai Fengxian District Central Hospital Joint Center for Translational Medicine, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal UniversityEast China Normal University and Shanghai Fengxian District Central Hospital Joint Center for Translational Medicine, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal UniversityEast China Normal University and Shanghai Fengxian District Central Hospital Joint Center for Translational Medicine, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal UniversityEast China Normal University and Shanghai Fengxian District Central Hospital Joint Center for Translational Medicine, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal UniversityEast China Normal University and Shanghai Fengxian District Central Hospital Joint Center for Translational Medicine, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal UniversityEast China Normal University and Shanghai Fengxian District Central Hospital Joint Center for Translational Medicine, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal UniversityEast China Normal University and Shanghai Fengxian District Central Hospital Joint Center for Translational Medicine, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal UniversityEast China Normal University and Shanghai Fengxian District Central Hospital Joint Center for Translational Medicine, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal UniversityEast China Normal University and Shanghai Fengxian District Central Hospital Joint Center for Translational Medicine, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal UniversityDivision of Biomedical Statistics and Informatics, Mayo Clinic College of MedicineEast China Normal University and Shanghai Fengxian District Central Hospital Joint Center for Translational Medicine, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal UniversityEast China Normal University and Shanghai Fengxian District Central Hospital Joint Center for Translational Medicine, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal UniversityEast China Normal University and Shanghai Fengxian District Central Hospital Joint Center for Translational Medicine, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal UniversityProstate cancers often become castration resistant due to alternative expression of androgen receptor (AR) splice variants. Here, the authors screened a library of natural compounds and identified Ailanthone as a potent inhibitor of AR through its binding to the co-chaperone protein p23 that, by preventing AR interaction with HSP90, results in ubiquitin/proteasome-mediated degradation of the receptor.https://doi.org/10.1038/ncomms13122 |